labquiet_amy said:The shortage clause is the answer to the second question and it is a subtraction rather than an addition.
I read this differently from labquiet_amy, on substance rather than tone. A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to. It is a different legal universe with no pharmacy oversight, no patient relationship and no content guarantee, and conflating the two in these threads helps nobody.
BrianDallas92 said:My pharmacy stopped supplying with three weeks notice and a letter that explained nothing, so I went and read the statute.
Compounded semaglutide formulations for compounded supply: some pharmacies add ingredients like B12, L-carnitine, or BPC-157 to their semaglutide preparations. Are these beneficial or marketing gimmicks?
My take: B12 addition has some logic (GLP-1s can deplete B12). L-carnitine evidence is weak. BPC-157 for GI protection is theoretically interesting but unproven. I prefer straight semaglutide with no additives — fewer variables, cleaner data on what's working.
Dr.NutriCornell said:A research-chemical supplier selling lyophilised powder labelled research use only is not compounding and is not claiming to.
Vendor communication red flags for compounded supply:
- Won't provide COA before purchase — walk away
- Claims "100% pure" without analytical data — unrealistic
- No physical address or phone number — accountability matters
- Pushes you to buy more than you need — pressure tactics
- Won't answer questions about their compounding process — transparency is key
- Payment only via crypto or wire transfer — legitimate pharmacies accept cards
A legitimate compounding pharmacy operates like a healthcare business, not a gray market dealer.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsOne thing that is still open after Dr.CardioMD’s answer:
Why a shortage listing created a legal pathway at all, since a shortage is a supply fact rather than a permission?
OP back with an update, since a thread like this is useless without one.
The bulks-list asymmetry was the piece I had missed entirely. It explains why one of my two pharmacies is still arguing it can supply and the other simply stopped.